Form 4: Dyne Therapeutics Director Dirk Kersten Reports Stock Sales

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) stock on September 16 and 17, 2024, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Dirk Kersten, a director of Dyne Therapeutics, reported the sale of common stock on September 16 and 17, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (FCF IV) on April 9, 2024.
• On September 16, 2024, 1,320 shares were sold at a weighted average price of $35.04, with prices ranging from $35.00 to $35.08.
• On September 17, 2024, 3,272 shares were sold at a weighted average price of $35.13, with prices ranging from $35.00 to $35.22.
• Following these transactions, Dirk Kersten indirectly beneficially owns 393,831 shares through FCF IV and 5,795,364 shares through ForDyne B.V.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock sales by a director. It doesn't inherently convey positive or negative sentiment, as the sales were conducted under a pre-arranged trading plan.

Industry Context

Insider transactions are routinely monitored by investors as they can provide signals, though not always definitive, about a company's prospects. Sales under 10b5-1 plans are less informative since they are pre-scheduled.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The sales are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates